• Home
  • Search Results
  • βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure.

βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure.

Journal of molecular and cellular cardiology (2010-11-03)
Julio Cesar Batista Ferreira, Patricia Chakur Brum, Daria Mochly-Rosen
ABSTRACT

Cardiac hypertrophy is a complex adaptive response to mechanical and neurohumoral stimuli and under continual stressor, it contributes to maladaptive responses, heart failure and death. Protein kinase C (PKC) and several other kinases play a role in the maladaptative cardiac responses, including cardiomyocyte hypertrophy, myocardial fibrosis and inflammation. Identifying specific therapies that regulate these kinases is a major focus of current research. PKC, a family of serine/threonine kinases, has emerged as potential mediators of hypertrophic stimuli associated with neurohumoral hyperactivity in heart failure. In this review, we describe the role of PKC isozymes that is involved in cardiac hypertrophy and heart failure. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure".

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Protein Kinase Cα antibody produced in rabbit, whole antiserum
Sigma-Aldrich
Anti-Protein Kinase Cβ2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-Protein Kinase Cβ2 antibody produced in mouse, clone PK-B26, ascites fluid
Sigma-Aldrich
Anti-Protein Kinase Cε antibody produced in rabbit, whole antiserum
Sigma-Aldrich
Anti-Protein Kinase Cβ2 antibody produced in rabbit, 0.5 mg/mL, affinity isolated antibody

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.